Gut microbiota analysis may help prevent the more serious effects of COVID-19. With this premise, Microviable seeks funding to design a predictive model and open the possibility of designing treatments from Spain.
El Comercio (Diario de Asturias), highlights Microviable’s activity in “the long-term isolation and storage of the microbiota under viable conditions, the analysis of its composition and, finally, the development of microbiome-based therapies. The first two business lines of Microviable, the collection of faecal samples guaranteeing the anaerobiosis (absence of oxygen) conditions with the patented GutAlive device, and the storage service, are already fully active. The GutAlive kit sales already reach five countries and more than half of the researchers or clinicians who know it, want to try it.